<--- Back to Details
First PageDocument Content
Medicine / Transplantation medicine / Clinical medicine / Hematopoietic stem cell transplantation / Fludarabine / Alemtuzumab / Graft-versus-host disease / Primary immunodeficiency / Leukemia / Allotransplantation / Total body irradiation / ThioTEPA
Date: 2010-01-13 06:38:42
Medicine
Transplantation medicine
Clinical medicine
Hematopoietic stem cell transplantation
Fludarabine
Alemtuzumab
Graft-versus-host disease
Primary immunodeficiency
Leukemia
Allotransplantation
Total body irradiation
ThioTEPA

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Add to Reading List

Source URL: www.nature.com

Download Document from Source Website

File Size: 159,54 KB

Share Document on Facebook

Similar Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEMTRADA safely and effectively. See full prescribing information for LEMTRADA. LEMTRADA® (alemtuzumab) injection,

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEMTRADA safely and effectively. See full prescribing information for LEMTRADA. LEMTRADA® (alemtuzumab) injection,

DocID: 1tfam - View Document

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Allogeneic hematopoietic SCT for patients with autoimmune diseases

DocID: 1pQwt - View Document

UCT  T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG Nicolas Novitzky PhD, FCP(SA)

UCT T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG Nicolas Novitzky PhD, FCP(SA)

DocID: 1k3Lh - View Document

alemtuzumab (Lemtrada) Ordnat Införande i Samverkan DatumVersion 2.0 Ett samarbetsprojekt mellan Sveriges landsting & Regioner  Alemtuzumab (Lemtrada) vid skovvis förlöpande MS

alemtuzumab (Lemtrada) Ordnat Införande i Samverkan DatumVersion 2.0 Ett samarbetsprojekt mellan Sveriges landsting & Regioner Alemtuzumab (Lemtrada) vid skovvis förlöpande MS

DocID: 1bN6B - View Document

Pharmacology / Medicine / Natalizumab / Alemtuzumab / Fingolimod / Clinical trial / Immunosuppressants / Immunology / Multiple sclerosis

7.10 ALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). Purpose of Application

DocID: 12AuW - View Document